ES2052699T3 - Vacuna contra la gripe. - Google Patents

Vacuna contra la gripe.

Info

Publication number
ES2052699T3
ES2052699T3 ES88300951T ES88300951T ES2052699T3 ES 2052699 T3 ES2052699 T3 ES 2052699T3 ES 88300951 T ES88300951 T ES 88300951T ES 88300951 T ES88300951 T ES 88300951T ES 2052699 T3 ES2052699 T3 ES 2052699T3
Authority
ES
Spain
Prior art keywords
sienenes
cells
influenza
stigenate
viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88300951T
Other languages
English (en)
Inventor
John Sydney Oxford
James Searl Robertson
Geoffrey Christopher Schild
David Arthur John Tyrrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Application granted granted Critical
Publication of ES2052699T3 publication Critical patent/ES2052699T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UNA CEPA DE VIRUS PARA LA GRIPE, ESPECIALMENTE GRRIPE HUMANA DE LOS TIPOS A O B, PARA USAR EN LA FORMULACION DE VACUNAS, SE ELIGE POR UN PROCEDIMIENTO QUE CONSISTE EN AISLAR VIRUS DE GRIPE ASPIRANTE EN HUEVOS DE GALLINAS EMBRIONADOS, DETERMINAR SI TIENEN SIMILITUDES ANTIGENAS A LAS CEPAS, QUE SON LAS MISMAS EXCEPTO QUE HAN SIDO AISLADAS DE CELULAS EXCLUSIVAMENTE DE CRECIMIENTO EN ANIMALES, SE PUEDE DECIR QUE SON "IGUAL QUE CELULAS", Y SELECCIONAR POR LO MENOS UNA CEPA IGUAL QUE CELULA, O UNO DE SUS PROMOTORES, QUE TIENEN SUS GENES HA Y NA PARA LA VACUNA.
ES88300951T 1987-02-18 1988-02-04 Vacuna contra la gripe. Expired - Lifetime ES2052699T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878703696A GB8703696D0 (en) 1987-02-18 1987-02-18 Influenza vaccine

Publications (1)

Publication Number Publication Date
ES2052699T3 true ES2052699T3 (es) 1994-07-16

Family

ID=10612471

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88300951T Expired - Lifetime ES2052699T3 (es) 1987-02-18 1988-02-04 Vacuna contra la gripe.

Country Status (9)

Country Link
US (1) US5162112A (es)
EP (1) EP0279563B1 (es)
JP (1) JP2525734B2 (es)
AT (1) ATE104698T1 (es)
AU (1) AU613012B2 (es)
CA (1) CA1335790C (es)
DE (1) DE3889138T2 (es)
ES (1) ES2052699T3 (es)
GB (2) GB8703696D0 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012060678A3 (es) * 2010-11-02 2012-07-19 Zepeda Lopez Hector Manuel Vacunas novedosas contra el virus de la influencia pandémica a/h1n1

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374717A (en) * 1992-09-30 1994-12-20 The United States Of America As Represented By The Secretary Of Health And Human Services Sequences of the hemagglutinins of recent strains of influenza type B virus
CA2164946A1 (en) * 1993-06-11 1994-12-22 Peter Palese High yielding influenza viruses
FR2761698B1 (fr) 1997-04-04 1999-05-07 Pasteur Merieux Serums Vacc Methode de titrage d'une composition virale complexe
KR20070058440A (ko) * 2004-07-02 2007-06-08 헨리 엘 니만 복제 선택 재조합 및 그것의 용도
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
ES2359214T5 (es) * 2005-11-01 2014-10-08 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual por tratamiento con beta-propiolactona
EP2251034B1 (en) 2005-12-02 2018-02-14 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
WO2008032219A2 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
CN101553252A (zh) * 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
WO2008153236A1 (en) * 2007-06-15 2008-12-18 Protheon Co., Ltd An attenuated influenza virus and a live vaccine comprising the same
WO2009081172A1 (en) * 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
CA2797059A1 (en) * 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
EP2704740B1 (en) 2011-05-04 2016-10-05 Streck, Inc. Inactivated swine flu virus and methods of preparing it
US9579374B2 (en) 2013-12-04 2017-02-28 The Johns Hopkins University Method for rapidly designing pharmaceutical preparations for preventing viral infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE662899A (es) * 1964-04-22
US4040905A (en) * 1971-10-27 1977-08-09 The United States Government Sub-human primate diploid cell lines as substrates for virus vaccine production

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012060678A3 (es) * 2010-11-02 2012-07-19 Zepeda Lopez Hector Manuel Vacunas novedosas contra el virus de la influencia pandémica a/h1n1

Also Published As

Publication number Publication date
EP0279563B1 (en) 1994-04-20
GB8802507D0 (en) 1988-03-02
GB2202327A (en) 1988-09-21
US5162112A (en) 1992-11-10
DE3889138T2 (de) 1994-08-04
DE3889138D1 (de) 1994-05-26
AU1191188A (en) 1988-08-25
ATE104698T1 (de) 1994-05-15
EP0279563A2 (en) 1988-08-24
JP2525734B2 (ja) 1996-08-21
GB8703696D0 (en) 1987-03-25
GB2202327B (en) 1991-05-15
AU613012B2 (en) 1991-07-25
CA1335790C (en) 1995-06-06
JPS63264532A (ja) 1988-11-01
EP0279563A3 (en) 1989-10-25

Similar Documents

Publication Publication Date Title
ES2052699T3 (es) Vacuna contra la gripe.
ES2113881T3 (es) Derivados y analogos de acido 2-desoxi-2,3-didehidro-n-acetil neuraminico y su utilizacion como agentes antivirales.
ES2040727T3 (es) Un proceso para preparar una formulacion en aerosol en solucion de un analogo.
ES2187505T3 (es) Elementos cis de proteinas de cuerpo oleoso como señales reguladoras.
MX9203458A (es) Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
ES2078214T3 (es) Deteccion de virus mediante amplificacion e hibridacion.
ES2054676T5 (es) Regulacion de transcripcion especifica de semillas.
ES2142874T3 (es) Preparacion de antigenos y de vacunas de virus de la enfermedad misteriosa, antigenos y vacunas obtenidas para la prevencion de esta enfermedad.
ES2035818T3 (es) Mutantes de delecion de la timidin-kinasa del virus del herpes bovino-1, vacunas contra la rinotraqueitis bovina infecciosa que los contienen y metodos para su produccion y uso.
ES2150419T3 (es) Procedimiento de atenuacion bacteriana y vacuna.
ES8900007A1 (es) Un metodo para producir normas orales frente a virus de hepatitis-b.
ES2052478T1 (es) Particulas retrovirales no replicantes producidas de forma recombinante empleadas como agentes antivirales e inmunogenos.
ES2040847T3 (es) Un procedimiento para preparar una composicion farmaceutica que contiene una sal de litio.
ES2056565T3 (es) Virus recombinante de la enfermedad de marek.
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
ES2142864T3 (es) Procedimiento y medio de cultivo para la obtencion de celulas infectadas por un virus asociado a la esclerosis en placas.
ES2133316T3 (es) Secuencias peptidicas especificas de las fases hepaticas de p. falciparum portadoras de epitopos capaces de estimular los linfocitos t.
ES2095241T3 (es) Secuencias oligonucleotidicas para la amplificacion del genoma de los retrovirus del tipo hiv-2 y siv, y sus aplicaciones al diagnostico in vitro de las infecciones debidas a estos virus.
ES2031883T3 (es) Un metodo para preparar una combinacion antiviral.
ES2061603T3 (es) Mutantes viricos de la rinotraqueitis bovina infecciosa, vacunas que los contienen, metodos para la produccion de los mismos y metodos para el empleo de los mismos.
Tafuri et al. Reactive oxygen metabolites in alpha-herpesvirus-seropositive Mediterranean buffaloes (Bubalus bubalis): A preliminary study
ES2061558T3 (es) Sondas de hibridacion de acidos nucleicos de papilomavirus humanos y metodos para su empleo.
DK76688D0 (da) Vaccine indeholdende f-proteinet fra aids-virus
ES2191842T3 (es) Interleucina-8 como agente antiviral y antitumoral.
ES2085888T3 (es) Composicion de vacuna.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 279563

Country of ref document: ES